Results 131 to 140 of about 545,250 (204)

Identification of C-mannosylation in a receptor tyrosine kinase AXL. [PDF]

Glycobiology
Mori K, Suzuki T, Waki U, Hayashi S, Kadono S, Kawahara R, Takeuchi M, Mizuta H, Dohmae N, Katayama R, Simizu S.   +10 more
europepmc   +1 more source

A pharmacovigilance study of thromboembolism events associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors based on FAERS database. [PDF]

Sci Rep
Tang Z, Song H, Pan L, Zhang M, Li S, Li W, Chen W, Wang X.   +7 more
europepmc   +1 more source

Risk of Moderate to Severe Ocular Surface Disease Associated with Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Therapy: A Multicenter Cohort Study. [PDF]

Ophthalmol Ther
Tsao YT, Kang EY, Wu CE, Hung N, Chen HC, Hsiao CH.   +5 more
europepmc   +1 more source

Longitudinal pharmacogenomic analysis of refractory lung cancer to identify therapeutic candidates for epidermal growth factor receptor-tyrosine kinase inhibitor resistance subclones. [PDF]

Exp Mol Med
Yu N, Hwang M, Ahn BC, Lee Y, Hong S, Sim H, Song BR, Kim S, Park C, Han JY.   +9 more
europepmc   +1 more source

Novel Para-Phenylenediamine-Based Derivatives as Receptor Tyrosine Kinase-like Orphan Receptor 1 (ROR1) Inhibitors: An In Vitro Preliminary Characterization. [PDF]

ChemMedChem
Smaldone G, Miranda MR, Di Matteo F, Napolitano V, Aliberti M, Musella S, Di Sarno V, Lauro G, Bifulco G, Pepe G, Aquino G, Tecce MF, Gomez-Monterrey IM, Campiglia P, Ostacolo C, Bertamino A, Vestuto V, Ciaglia T.   +17 more
europepmc   +1 more source

The expanding role of the receptor tyrosine kinase MET as a therapeutic target in non-small cell lung cancer. [PDF]

Cell Rep Med
Sattler M, Salgia R.
europepmc   +1 more source

Screening of tyrosine phosphatase SHP2 (PTPN11) inhibitors from natural products with therapeutic potential for receptor tyrosine kinase-driven cancer. [PDF]

J Pharm Anal
Chen L, Ke D, Jiang Z, Luo R, Li J, Zheng L, Liang G.   +6 more
europepmc   +1 more source

Do germline genetic variants affect the efficacy of epidermal growth factor receptor tyrosine kinase inhibitors? [PDF]

Transl Cancer Res
Masago K, Fujita S, Sasaki E, Horio Y.
europepmc   +1 more source

Resistance patterns of non-small cell lung cancer treated with third-generation epidermal growth factor receptor-tyrosine kinase inhibitors. [PDF]

Am J Cancer Res
Chen N, Zhao F, Yang L, Tan X, Wang D, Ye X, Wei Z.   +6 more
europepmc   +1 more source

Receptor Tyrosine Kinase Signaling [PDF]

, 2015
openaire   +1 more source